Oruka Therapeutics (NASDAQ:ORKA) Shares Down 5% – Time to Sell?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) shares fell 5% during trading on Monday . The company traded as low as $87.57 and last traded at $86.5970. 43,076 shares traded hands during trading, a decline of 96% from the average daily volume of 1,112,356 shares. The stock had previously closed at $91.14.

Wall Street Analyst Weigh In

ORKA has been the subject of several analyst reports. Wedbush reissued an “outperform” rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Guggenheim reaffirmed a “buy” rating and set a $200.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. BTIG Research reiterated a “buy” rating and set a $151.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Piper Sandler reissued an “overweight” rating and issued a $180.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Finally, Weiss Ratings upgraded Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Oruka Therapeutics has an average rating of “Moderate Buy” and an average target price of $134.30.

Oruka Therapeutics Trading Down 0.6%

The firm has a market capitalization of $6.10 billion, a P/E ratio of -45.37 and a beta of -0.34. The stock’s 50-day simple moving average is $94.92 and its 200-day simple moving average is $68.59.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, equities research analysts expect that Oruka Therapeutics, Inc. will post -2.33 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Lawrence Otto Klein sold 75,000 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the completion of the sale, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at $84,996,011.40. This trade represents a 7.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $106.66, for a total value of $1,066,600.00. Following the sale, the senior vice president directly owned 15,312 shares of the company’s stock, valued at approximately $1,633,177.92. This represents a 39.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 158,116 shares of company stock valued at $13,523,783. 23.49% of the stock is owned by insiders.

Hedge Funds Weigh In On Oruka Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System increased its holdings in Oruka Therapeutics by 15,941.3% during the second quarter. California State Teachers Retirement System now owns 3,428,023 shares of the company’s stock worth $326,245,000 after buying an additional 3,406,653 shares during the last quarter. Braidwell LP purchased a new position in Oruka Therapeutics in the second quarter valued at about $26,473,000. Nykredit A S bought a new position in shares of Oruka Therapeutics during the 2nd quarter valued at approximately $29,000. Natural Investments LLC bought a new position in shares of Oruka Therapeutics during the 2nd quarter valued at approximately $202,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Oruka Therapeutics by 517.1% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 104,310 shares of the company’s stock valued at $9,927,000 after acquiring an additional 87,408 shares during the period. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.